Navigation Links
XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Date:2/7/2008

VALLEY COTTAGE, N.Y., Feb. 7 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) announced today that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the 10th Annual BIO CEO & Investor Conference. Mr. Bentsur will present an overview of the Company including a discussion of Bicifadine, the Company's late-stage clinical compound for the treatment of diabetic neuropathic pain. Mr. Bentsur's presentation will take place on Wednesday, February 13, 2008 at 1:15 pm EST at the Waldorf Astoria Hotel in New York City.

A live webcast of the presentation will be available at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=XTL&item_id=175250 2. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT XTL BIOPHARMACEUTICALS LTD. XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL is also developing novel pre-clinical HCV small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (Nasdaq: XTLB; TASE
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
2. Nabi Biopharmaceuticals to Present at the BMO Capital Markets Focus on Healthcare Conference
3. China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results
4. Nabi Biopharmaceuticals Stockholders Approve Asset Sale
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals Proposed Asset Sale
7. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 9th Annual Health Care Conference
8. XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals Announces Mailing of Definitive Proxy Statement and Release Date of Third Quarter 2007 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... April 17, 2015 LC Sciences ... technologies, announced today that it is seeking beta ... innovative multiplex PCR based targeted sequencing technology. The ... analysis, that enables accurate detection of rare variants. ... Omega-Primer™ technologies. The company will collaborate with beta ...
(Date:4/16/2015)... 16, 2015 Cambridge Semantics ... driven by Semantic Web technology, and Informa ... and services for the academic and scientific, professional ... joint solution ‘Smart Data Lake for Clinical Trial ... the 2015 Bio-IT ‘Best of Show’ Award. ...
(Date:4/16/2015)... 2015  Schulman Associates IRB, Inc., the industry-leading central ... long-term lease on Laboratory Drive in the heart of ... The location will house review board and service staff, ... reviews and customer service to clients. ... in the deal, while Capital Associates Management, LLC represented ...
(Date:4/16/2015)... IA (PRWEB) April 16, 2015 ... announces that the prestigious 2015 Borlaug CAST Communication ... faculty member at Tuskegee University in Alabama. Award ... written material; public presentations; and/or the use of ... in all three areas. As a specialist in ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2
... Nov. 2 Cardium Therapeutics (NYSE Amex: CXM ... notification with the U.S. Food and Drug Administration (FDA) ... candidate. Excellagen XL is an advanced wound ... topical gel designed for use by physicians in patients ...
... trial points to the first new lupus treatment in over ... Lupus Research Institute (LRI) and its National Coalition of state ... GlaxoSmithKline for achieving an historical landmark - the second positive ... tested new drug developed specifically for people with systemic lupus. ...
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced the ... 3 study at the 47th Annual Meeting of the ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) , Mark ... Diseases, Chair of the Infection Prevention and Control Unit ...
Cached Biology Technology:Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 2Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 3Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 4Lupus Research Institute: Benlysta(TM) Trial Results in an Historic Research Breakthrough and Victory for People With Lupus 2Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 2Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 3Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 4
(Date:3/23/2015)... YORK , March 23, 2015   HOYOS ... property management company, today announced that the Company will ... for both enterprise and consumers at Connect:ID on March ... HOYOS Labs will highlight the IEEE Biometric ... TM ; and enterprise access control system. BOPS ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
(Date:3/18/2015)... Florida , March 18, 2015 ... as businesses, new revolutionary smart wallets and apps continue to ... Companies currently entrenched in the mobile payment industry in focus ... Group Holding Ltd. (NYSE: BABA ), Apple Inc. ... GOOG ) and Facebook Inc. (NASDAQ: FB ) ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... A. High, M.D., of The Children,s Hospital of Philadelphia ... research in the bleeding disorder hemophilia when she received ... Society of Hematology (ASH) at its annual meeting on ... late Nobel Prize laureate E. Donnall Thomas, the award ...
... A study in mice shows how a breakdown of ... associated with Alzheimer,s disease. The results published in ... called pericytes may provide novel targets for treatments and ... vascular system may contribute to the development of Alzheimer,s ...
... not climate change as is widely believed, is the ... in the Andes mountains, according to a new study ... Frogs living at higher elevations can tolerate increasing ... optimal temperature range for Batrachochytrium dendrobatidis , or ...
Cached Biology News:National award honors CHOP scientist for career work in gene therapy for hemophilia 2Study breaks blood-brain barriers to understanding Alzheimer's 2Study breaks blood-brain barriers to understanding Alzheimer's 3Disease, not climate change, fueling frog declines in the Andes, study finds 2Disease, not climate change, fueling frog declines in the Andes, study finds 3
MOUSE ANTI SIMIAN VIRUS 5 Immunogen: Simian virus 5...
MOUSE ANTI SIMIAN VIRUS 5:FITC Immunogen: Simian virus 5...
MOUSE ANTI HUMAN MBP (67-74) Immunogen: Human myelin basic protein...
... The DNAclear cDNA Purification Kit is designed ... reactions such as cDNA synthesis and PCR. The ... from 1 ng to 3 g can be ... of three steps: 1) DNA is bound to ...
Biology Products: